Biomedical Technology Optimization and Dissemination Center (BTOD) (RM1 - Clinical Trial Not Allowed)
Supports centers that optimize late-stage biomedical technologies and sustainably disseminate them to the wider research community in areas within the NIGMS mission; clinical trials are not allowed.
Funder: National Institutes of Health
Due Dates: January 28, 2027 (Applications) | May 28, 2027 (Applications) | January 28, 2028 (Applications) | May 26, 2028 (Applications) | January 29, 2029 (Final applications)
Funding Amounts: Up to $850,000 in direct costs annually for up to 5 years, excluding equipment and consortium F&A costs
Summary: Supports centers optimizing late-stage biomedical technologies and sustainably disseminating them across the biomedical research community.
Key Information: Projects must fit the NIGMS mission and integrate technology optimization, collaborative biomedical testing, and community engagement; clinical trials are prohibited.
Description
The National Institute of General Medical Sciences (NIGMS) supports Biomedical Technology Optimization and Dissemination (BTOD) Centers through the RM1 mechanism. Centers refine functional technologies that have demonstrated laboratory feasibility but still require specialized expertise, making them robust and accessible to broader biomedical research communities. A center may optimize one technology or integrate complementary technologies addressing a shared class of research problems.
Supported areas include analytical biochemistry, chemical biology, high-throughput methods, spatial omics, structural biology, imaging, molecular biology, cell manipulation, computation, and modeling. Centers combine Technology Optimization Projects (TOPs), collaborative Driving Biomedical Projects (DBPs), and Community Engagement (CE). The goal is widespread, sustainable technology adoption by experts and non-experts, independent of continued center funding—not early-stage development or user access to mature technologies.
